Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27950450 | 0.77 | PRSS1 (0.53) | PRSS1KCNA3MAOAMAOB | |
| SCHEMBL3616028 | 0.75 | DRD2 (0.51) | ALDH1A1NPSR1NOS1HMOX2 | |
| SCHEMBL27936389 | 0.75 | PRSS1 (0.55) | PRSS1KCNA3 | |
| SCHEMBL27950428 | 0.75 | PRSS1 (0.55) | PRSS1KCNA3 | |
| SCHEMBL17911614 | 0.70 | KCNA3 (0.48) | PRSS1KCNA3NPC1MAPTRAB9A | |
| SCHEMBL12691913 | 0.70 | PLA2G2A (0.47) | HRH3PRSS1KCNA3MAOA | |
| SCHEMBL27963116 | 0.70 | PLA2G2A (0.47) | HRH3PRSS1KCNA3MAOA | |
| SCHEMBL7389768 | 0.69 | MAPK1 (0.57) | ALOX15SMN1; SMN2ALDH1A1NPSR1MAOB | |
| SCHEMBL29696901 | 0.68 | MAPK1 (0.56) | ALOX15PRSS1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL15923561 | 0.68 | TSHR (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168125-A1 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | DONSBACH, MARTIN (DE) | 2010-07-01 | — | — | US | disclosed |
| EP-2137185-A2 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | Gmeiner, Dr. Peter (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008113559-A2 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | SCHWARZ PHARMA AG (DE) | 2008-09-25 | — | — | WO | disclosed |
| EP-1972628-A1 | Indolizines and aza-analog derivatives thereof as CNS active compounds | SCHWARZ PHARMA AG (DE) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168125-A1 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | INMT, AANAT, AZI2 | HRH3 1522/4885ALOX15 2419/4885PRSS1 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.